Pfizer Inc Cash Flow Conversion Efficiency
Pfizer Inc cash flow conversion efficiency. Based on the latest financial reports, Pfizer Inc (PFE) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($835.00 Million) by net assets ($85.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pfizer Inc (1989–2025)
Cash flow conversion efficiency of Pfizer Inc from 1989 to 2025. This chart illustrates how Pfizer Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Pfizer Inc for real-time trading data and today's change.
Pfizer Inc Cash Flow Conversion Ratio Explained
Pfizer Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pfizer Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pfizer Inc ranked by their cash flow conversion efficiency. Also see Pfizer Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sumitomo Mitsui Financial Group Inc
NYSE:SMFG
|
0.471x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.127x |
|
Walt Disney Company DRC
BA:DISN
|
0.042x |
|
The TJX Companies Inc
NYSE:TJX
|
0.108x |
|
Marvell Technology Group Ltd
NASDAQ:MRVL
|
0.033x |
|
Southern Copper Corporation
NYSE:SCCO
|
0.156x |
|
Banco Santander S.A
F:BSDK
|
0.080x |
|
Deutsche Telekom AG
XETRA:DTE
|
0.117x |
Annual Cash Flow Conversion Efficiency for Pfizer Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Pfizer Inc from 1989 to 2025. Review how much free cash does Pfizer Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $86.78 Billion | $11.71 Billion | 0.135x | -6.33% |
| 2024-12-31 | $88.50 Billion | $12.74 Billion | 0.144x | +47.79% |
| 2023-12-31 | $89.29 Billion | $8.70 Billion | 0.097x | -68.07% |
| 2022-12-31 | $95.92 Billion | $29.27 Billion | 0.305x | -27.45% |
| 2021-12-31 | $77.46 Billion | $32.58 Billion | 0.421x | +85.35% |
| 2020-12-31 | $63.47 Billion | $14.40 Billion | 0.227x | +14.37% |
| 2019-12-31 | $63.45 Billion | $12.59 Billion | 0.198x | -20.07% |
| 2018-12-31 | $63.76 Billion | $15.83 Billion | 0.248x | +8.00% |
| 2017-12-31 | $71.66 Billion | $16.47 Billion | 0.230x | -13.50% |
| 2016-12-31 | $59.84 Billion | $15.90 Billion | 0.266x | +19.02% |
| 2015-12-31 | $65.00 Billion | $14.51 Billion | 0.223x | -5.28% |
| 2014-12-31 | $71.62 Billion | $16.88 Billion | 0.236x | +1.67% |
| 2013-12-31 | $76.62 Billion | $17.77 Billion | 0.232x | +11.05% |
| 2012-12-31 | $81.68 Billion | $17.05 Billion | 0.209x | -14.77% |
| 2011-12-31 | $82.62 Billion | $20.24 Billion | 0.245x | +88.78% |
| 2010-12-31 | $88.27 Billion | $11.45 Billion | 0.130x | -29.24% |
| 2009-12-31 | $90.45 Billion | $16.59 Billion | 0.183x | -41.94% |
| 2008-12-31 | $57.74 Billion | $18.24 Billion | 0.316x | +54.05% |
| 2007-12-31 | $65.12 Billion | $13.35 Billion | 0.205x | -17.58% |
| 2006-12-31 | $70.72 Billion | $17.59 Billion | 0.249x | +12.05% |
| 2005-12-31 | $66.36 Billion | $14.73 Billion | 0.222x | -6.40% |
| 2004-12-31 | $68.88 Billion | $16.34 Billion | 0.237x | +32.11% |
| 2003-12-31 | $65.38 Billion | $11.74 Billion | 0.180x | -64.82% |
| 2002-12-31 | $19.95 Billion | $10.18 Billion | 0.510x | +0.80% |
| 2001-12-31 | $18.29 Billion | $9.26 Billion | 0.506x | +31.40% |
| 2000-12-31 | $16.08 Billion | $6.20 Billion | 0.385x | -60.25% |
| 1999-12-31 | $3.15 Billion | $3.06 Billion | 0.970x | +191.62% |
| 1998-12-31 | $8.81 Billion | $2.93 Billion | 0.332x | +68.95% |
| 1997-12-31 | $8.28 Billion | $1.63 Billion | 0.197x | -33.32% |
| 1996-12-31 | $7.00 Billion | $2.07 Billion | 0.295x | -10.02% |
| 1995-12-31 | $5.55 Billion | $1.82 Billion | 0.328x | -3.87% |
| 1994-12-31 | $4.36 Billion | $1.49 Billion | 0.341x | +5.48% |
| 1993-12-31 | $3.90 Billion | $1.26 Billion | 0.323x | +90.52% |
| 1992-12-31 | $4.75 Billion | $807.00 Million | 0.170x | +1.36% |
| 1991-12-31 | $5.06 Billion | $847.60 Million | 0.167x | -0.33% |
| 1990-12-31 | $5.12 Billion | $860.50 Million | 0.168x | +16.84% |
| 1989-12-31 | $4.56 Billion | $655.80 Million | 0.144x | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more